Annual income statement for Kohjin Bio, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3,947 | 4,743 | 4,770 | 5,206 | 4,939 |
| Cost of Revenue | |||||
| Gross Profit | 2,039 | 2,454 | 1,881 | 2,366 | 1,857 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,974 | 3,476 | 4,173 | 4,267 | 4,606 |
| Operating Profit | 973 | 1,267 | 597 | 939 | 333 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 922 | 1,244 | 636 | 1,015 | 332 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 588 | 830 | 385 | 795 | 251 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 588 | 830 | 385 | 795 | 251 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 588 | 830 | 385 | 795 | 251 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 117 | 165 | 76.8 | 165 | 50.4 |
| Dividends per Share |